In PTC, NOX4 expression is significantly higher in the presence of the BRAFV600E mutation [123], the most frequent genomic alteration found in PTC, present in around 40–60% of cases and associated with increased cancer-related mortality and thyroid cell dedifferentiation, as well [124,125]. Here, NOX4 is linked to cancer.